Angiogenesis and Proliferation Index in Patients with Acute Leukemia: A Prospective Study

Jothilingam, Prabhavati; Basu, Debdatta; Dutta, Tarun Kumar

doi:10.1155/2014/634874

Cited by 12 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies confirmed the increased MVD in AML bone marrow and showed also a correlation between the increase of MVD and the proliferation index of leukemic blasts [56] and the association between increased MVD and increased bone marrow VEGF levels, both parameters decreasing in patients who achieved disease remission following induction therapy [57] . Kuzu et al [58] showed a higher MVD in AML patients compared to controls, independent of cellularity or blast percentage; higher baseline MVD values in AML patients were associated with a shorter overall survival and thus are a negative prognostic factor.…”

Section: Angiogenesis In Aml Bone Marrow: Microvessel Densitymentioning

confidence: 76%

Angiogenesis in acute myeloid leukemia

Testa¹,

Castelli²

2020

JCMT

View full text Add to dashboard Cite

Angiogenesis is a word that refers to new blood vessel formation, and this process is of fundamental importance for physiological development and tissue homeostasis, as well as the genesis of several diseases, including tumors. Thus, studies carried out in the last years have shown that angiogenesis is essential for the growth of many solid tumors. Angiogenesis is also important for the growth of many hematological malignancies, including acute myeloid leukemia (AML). Endothelial cells are essential constituents of the bone marrow vascular niches, structures essential for the survival and maintenance of normal hematopoietic stem/progenitor cells. Bone marrow endothelial cells play an essential role in leukemia development and there is growing evidence that a targeting of both leukemic and endothelial cells of the leukemic vascular niche may improve the efficacy of antileukemic therapies. Bone marrow angiogenesis is frequently increased in AML, is morphologically evidenced as increased microvascular density, and is typically associated with some AML subtypes. The molecular mechanisms underlying the increased angiogenesis in some AML subtypes have been defined. In conclusion, a better understanding of angiogenesis as well as the fundamental interactions between bone marrow endothelial cells and leukemic stem cells may contribute to improve antileukemia treatments.

show abstract

Section: Angiogenesis In Aml Bone Marrow: Microvessel Densitymentioning

confidence: 76%

Angiogenesis in acute myeloid leukemia

Testa¹,

Castelli²

2020

JCMT

View full text Add to dashboard Cite

show abstract

“…Next, we separately analyzed the relationships between the drug sensitivity of tumor cells of patients with primary AML and the expression of lymphoid (T- and B-) and immature markers as well as the proliferation marker, Ki-67, which are indicators of an unfavorable prognosis for leukemia [39,40,41,42]. Resistance of tumor cells to doxorubicin correlated only with the expression of one T-cell marker, CD2 ( r = 0.51), whereas resistance to daunorubicin correlated directly with the expression of several T-cell markers (CD2, r = 0.16; CD3, r = 0.38; CD7, r = 0.07; and CD11c, r = 0.41), and the natural killer (NK) cell marker, CD56 ( r = 0.50).…”

Section: Resultsmentioning

confidence: 99%

Clinical and Prognostic Significance of Cell Sensitivity to Chemotherapy Detected In Vitro on Treatment Response and Survival of Leukemia Patients

Kolesnikova

Sen’kova

Tairova³

et al. 2019

JPM

View full text Add to dashboard Cite

Multidrug resistance (MDR) is a major challenge in leukemia treatment. The objective of this study was to identity predictors of MDR to allow for rapid and economical assessment of the efficacy of planned antitumor therapy for leukemia patients. The study included 113 patients with acute and chronic leukemias. Prior to antitumor therapy, we measured the sensitivity of tumor cells of patients to the panel of chemotherapeutic drugs, together with MDR1 mRNA and P-glycoprotein (P-gp) expression as one of the mechanisms of MDR, and compared these data with the response to therapy. The scales for leukemia patients according to therapy response, drug sensitivity of tumor cells, MDR1 mRNA and P-gp levels, and the presence of unfavorable immunological and cytogenetic markers were introduced for subsequent correlation analysis. We show that the drug resistance of tumor cells of leukemia patients estimated in vitro at diagnosis correlates with a poor response to chemotherapy and is usually combined with aberrant and immature immunological markers, cytogenetic abnormalities, and a high expression of MDR1 mRNA and P-gp. All together, these factors indicate unfavorable prognosis and low survival of leukemia patients. Thus, the sensitivity of tumor cells to chemotherapeutic drugs measured in vitro at diagnosis may have prognostic value for individual types of leukemia.

show abstract

“…However, there is strong evidence of increased angiogenesis in these "liquid" tumors as well. Increased microvessel density and/or infiltration of inflammatory cells is seen in bone marrow of patients suffering from virtually all types of HM [84,[108][109][110][111][112][113][114]. Increased microvessel density and endothelial cell mass plays an important role in providing nutrients and oxygen to malignant cells.…”

Section: Nanomedicines For Drug Delivery In Hematological Malignanciesmentioning

confidence: 99%